<?xml version="1.0" encoding="UTF-8"?>
<p id="Par30">Fingolimod is an oral immunomodulating agent that is primarily used to treat refractory multiple sclerosis [
 <xref ref-type="bibr" rid="CR76">76</xref>]. By structurally resembling the lipid sphingosine-1-phosphate (S1P), fingolimod can act as a highly potent functional antagonist of S1P1 receptors in the lymph node T cells [
 <xref ref-type="bibr" rid="CR76">76</xref>]. Similar to the immunomodulatory properties of IFN-I, fingolimod is regarded as a method of treating the SARS-CoV-2 triggered overactivation of immune responses [
 <xref ref-type="bibr" rid="CR77">77</xref>]. A non-randomized and open-label study is preparing to evaluate the efficacy of fingolimod for treating COVID-19 [
 <xref ref-type="bibr" rid="CR78">78</xref>].
</p>
